F J Pardo

Universidad de Navarra, Pamplona, Navarre, Spain

Are you F J Pardo?

Claim your profile

Publications (7)7.79 Total impact

  • Urology 01/2007; 70(3):126-126. · 2.42 Impact Factor
  • European Urology Supplements - EUR UROL SUPPL. 01/2007; 6(2):32-32.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The family of tumors derived from mesenchymal perivascular epithelioid cells (so-called PEComas) includes angiomyolipoma, lymphangioleiomyomatosis, clear cell sugar tumor of the lung, clear cell myomelanocytic tumor of ligamentum teres/falciform ligament, and abdominopelvic sarcoma of perivascular epithelioid cells. These tumors were characterized by coexpression of melanocytic (HMB-45) and muscle markers. MyoD1 transcription factor has crucial role in commitment and differentiation of mesenchymal progenitor cells to myogenic lineage. Antibodies to MyoD1 protein (nuclear immunoreactivity) have been shown highly valuable adjuncts in the diagnosis of rhabdomyosarcomas. To evaluate expression of the transcription factor MyoD1 in PEComas, we performed immunohistochemistry. Monoclonal antibody 5.8A for MyoD1 was used on a series of cases of formalin-fixed, paraffin-embedded angiomyolipoma (n = 19), lymphangioleiomyomatosis (n = 3), clear cell sugar tumor of the lung (n = 1), and abdominopelvic sarcoma of perivascular epithelioid cells (n = 2). All cases showed strong granular immunostaining in the tumor cell cytoplasm with the anti-MyoD1 antibody. Cytoplasmic reactivity was noted in the spindle cells, fat cells, and epithelioid cells. Nuclei were negative in all tumors studied, and a clean background was obtained. Several normal and neoplastic human tissues have also been immunostained for MyoD1 without any positive cytoplasmic staining, with the exception of 2 alveolar soft part sarcomas. Cytoplasmic immunostaining with monoclonal antibody 5.8A for MyoD1 in PEComas may correspond to cross-reactivity with an undetermined cytoplasmic protein. Great caution should be exercised in interpreting the immunostaining results with anti-MyoD1 antibody 5.8A.
    Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry 07/2003; 11(2):156-60. · 1.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The family of tumors derived from mesenchymal perivascular epithelioid cells (so-called PEComas) includes angiomyolipoma, lymphangioleiomyomatosis, clear cell sugar tumor of the lung, clear cell myomelanocytic tumor of ligamentum teres/falciform ligament, and abdominopelvic sarcoma of perivascular epithelioid cells. These tumors were characterized by coexpression of melanocytic (HMB-45) and muscle markers. MyoD1 transcription factor has crucial role in commitment and differentiation of mesenchymal progenitor cells to myogenic lineage. Antibodies to MyoD1 protein (nuclear immunoreactivity) have been shown highly valuable adjuncts in the diagnosis of rhabdomyosarcomas. To evaluate expression of the transcription factor MyoD1 in PEComas, we performed immunohistochemistry. Monoclonal antibody 5.8A for MyoD1 was used on a series of cases of formalin-fixed, paraffin-embedded angiomyolipoma (n = 19), lymphangioleiomyomatosis (n = 3), clear cell sugar tumor of the lung (n = 1), and abdominopelvic sarcoma of perivascular epithelioid cells (n = 2). All cases showed strong granular immunostaining in the tumor cell cytoplasm with the anti-MyoD1 antibody. Cytoplasmic reactivity was noted in the spindle cells, fat cells, and epithelioid cells. Nuclei were negative in all tumors studied, and a clean background was obtained. Several normal and neoplastic human tissues have also been immunostained for MyoD1 without any positive cytoplasmic staining, with the exception of 2 alveolar soft part sarcomas. Cytoplasmic immunostaining with monoclonal antibody 5.8A for MyoD1 in PEComas may correspond to cross-reactivity with an undetermined cytoplasmic protein. Great caution should be exercised in interpreting the immunostaining results with anti-MyoD1 antibody 5.8A. Angiomyolipoma (AML) is an unusual tumor of uncertain histiogenesis. 1 It is a member of the perivascular epithelioid cell family of tumors that show coexpression of muscle-specific markers and melanocytic markers. 2 Immunoreactivity for HMB-45 antigen has been demonstrated in angiomyolipomas. MyoD1 gene (chromosome 11p) encodes a Mr 45 kDa nuclear phosphoprotein. Myogenic transcriptional regulators such as myogenin and MyoD1 appear to play a critical role in the commitment of mesenchymal progenitor cells to the myogenic cell line. 3,4 Monoclonal antibodies have been developed against recombinant wild-type MyoD1 protein. 5 MyoD1 has been reported as a sensitive and specific marker for rhabdomyosarcoma. 6 Nuclear immunostaining has been defined as the criterion for MyoD1 positivity. Great caution should be exercised in interpreting the immunostaining results with anti-MyoD1 antibody 5.8A. Granular cytoplasmic immunoreactivity has been observed in a number of nonrhabdomyosarcoma tumors and normal tissues. 7–10 These results led us to evaluate the pattern of immunoreactivity of anti-MyoD1 5.8A monoclonal antibody in tumors derived from mesenchymal perivascular epithelioid cells (PEComas), such as angiomyolipomas, lymphangioleiomyomas, clear cell sugar tumors of the lung, and abdominopelvic sarcoma of perivascular epithelioid cells.
    Applied Immunohistochemistry 05/2003; 11(2):156-160. · 1.83 Impact Factor
  • Source
    Transplantation Proceedings 10/1999; 31(6):2283-4. · 0.95 Impact Factor
  • Source
    Transplantation Proceedings 10/1999; 31(6):2550-1. · 0.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We review some morphological aspects shared by all allografts. The main points are: 1) The expression of antigens of histocompatibility, essentially DR, allows the diagnosis of acute rejection with a significant specificity; 2) A lesion similar to "Quilty" effect may be seen in other allografts, and it is the first manifestation of an acute rejection; 3) Fine-needle aspiration biopsy may help in the follow-up of kidney transplant but has been demonstrated ineffective in other transplants; 4) The morphology of rejection is different according to the type of immunosuppressive therapy; 5) The basic lesions of chronic rejection are vascular, but chronic rejection may be diagnosed without vessels in the biopsy specimen, by the degree of atrophy of the parenchyma; 6) For the characterization of lymphomas in transplanted patients is necessary study the clonality of tumor cells, the gene rearrangement and the lymphoid subset; 7) Molecular Pathology may help in the early diagnosis of viral infections after transplantation.
    Revista de medicina de la Universidad de Navarra 01/1994; 38(4):189-94.